All In Biotech

Investigational drug · Phase 2

MK-2214

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Early Alzheimer's Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "MK-2214"

First trial start

2025

Jul 16, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MK-2214", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Early Alzheimer's Disease

Approved drugs for the same conditions: Alzheimer's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "MK-2214" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Early Alzheimer's Disease

  • SemagludtidePhase 32 trials

    Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease

  • CT1812Study Drug ActivePhase 22 trials

    Cognition Therapeutics · Early Alzheimer's Disease, Dementia With Lewy Bodies

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.